CD38 and Miyoshi myopathy: A recently reported subpopulation of Treg CD38+ was found to be more immunosuppressive than Tregs CD38− and were decreased in patients treated with daratumumab suggesting an additional mechanism of action for this anti-CD38 antibody used to treat MM patients.